trial

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

NCTId NCT03883360
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Withdrawn
Enrollment 0 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2050-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2050-01
Primary completion
2050-02
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Cannabidiol

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
Sheppard Pratt Health SystemCollaborator
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator

Sites

3 total
Los Angeles, United StatesBaltimore, United StatesCatonsville, United States

Linked catalysts

1
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumpt — primary completion2050-02

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE2
Primary Completion Date
2050-02
Status
WITHDRAWN
relationships
The graph out of here
drug
Cannabidiol
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
Sheppard Pratt Health System
company
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Psychotic Disorders
indication
Marijuana Abuse
indication
Schizophrenia
indication